Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Terminated

G-6-PDH Deficient Control (G-6-PDH CONTROL D), Catalogue Number PD2617 Product Usage: This product is intended for in vitro diagnostic use, in the quality control of Glucose-6-Phosphate Dehydrogenase in erythrocytes

FDA Recall Z-1254-2019 · Posted None

Recalling FirmRandox Laboratories Ltd.
Recall StatusTerminated
Product CodeJBL
Date Initiated2019-04-03
Date Terminated2019-10-09
Product Quantity14 kits

Reason for Recall

The target values and ranges in these lots are incorrect.

Firm Action

Randox sent an Urgent Medical Device Correction notification letters dated 4/2/19 to affected customers. The letter identified the affected product, problem and action to be taken: " Discontinue use of and quarantine any of the above devices immediately. " Discuss the contents of this notice with your Medical Director. " Review results generated with the affected batches in line with the clinical profile of the patient. " Inform all relevant staff members. If you have supplied or transferred any potentially affected product to another facility or organization, let that facility know of the recall immediately by providing a copy of this FSN and response form. " Complete and return the response form 12187-QA to [email protected] within five working days. For questions contact Randox Technical Services.

Root Cause

Nonconforming Material/Component

Distribution Pattern

The products were distributed to the following US states: IL, OH, NC, PA, WI, WV and Puerto Rico.

Official Source

View FDA Recall →

Source: FDA Enforcement Report / Recall database. Always confirm against the official FDA record.

↑